Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy最新文献

{"title":"Serum Lactate Dehydrogenase Is a Novel Predictor for the Severity in the Patients With MAFLD: A Cross-Sectional Study in Hefei, China.","authors":"Liang Yu, Shiming Bao, Feng Zhu, Yanyan Xu, Fuqiang Zu, Yanwei Liu, Runbeng Jiang, Wei Chen, Song Chen","doi":"10.2147/DMSO.S492153","DOIUrl":"10.2147/DMSO.S492153","url":null,"abstract":"<p><strong>Background & aims: </strong>The aim of this study was to assess the association between the level of lactate dehydrogenase (LDH) and the severity of metabolic syndrome (MetS) and Metabolic Associated Fatty Liver Disease (MAFLD) and the potential diagnostic value of LDH for identifying at-risk metabolic associated steatohepatitis (MASH).</p><p><strong>Methods: </strong>This cross-sectional, real-world retrospective study enrolled a total of 1118 obese patients in the department of bariatric surgery at the Second Affiliated Hospital of Anhui Medical University from January 1, 2018, to December 31, 2021. Of these, 855 were enrolled in the study cohort. MAFLD was defined as the presence or absence of fatty liver disease as suggested by histologic biopsy of liver or postoperative pathology slides, or even hematology, and meets one of the following three conditions: overweight or obesity, T2DM, and metabolic dysfunction (MetS). Serum LDH activity levels were measured in 885 patients, and logistic regression was used to analyze the relationship between LDH and metabolic syndrome and the severity of MAFLD.</p><p><strong>Results: </strong>In the study cohort of 855 obese patients, 604 (70.6%) had MetS. Patients with MetS (214.1[209.0-219.2]) had significantly higher serum LDH levels than those without MetS (188.7[181.6-195.9]). Particularly, serum LDH level was significantly higher in subjects with hypertension, central obesity, diabetes mellitus or hyperglycemia, elevated levels of triglycerides, or reduced levels of high-density lipoprotein than in those without. Moreover, LDH concentrations were grouped according to the total number of MetS components present in each patient, with Serum LDH levels gradually increase with the total number of MetS components. The MASH subjects had significantly higher LDH levels than the other three less severe non-MASH cohorts, including normal liver, simple fatty steatosis, and B.MASH. Logistic regression showed that LDH was significantly and positively correlated with MAFLD, B.MASH, MASH, at-risk MASH, fibrosis grade ≥1, fibrosis grade ≥2 and fibrosis grade ≥3.</p><p><strong>Conclusion: </strong>Increased LDH levels were significantly and independently associated with the presence and severity of metabolic syndrome and MAFLD, indicating that LDH could be used as a novel biomarker and clinical predictor of severity of metabolic syndrome and MAFLD.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"345-361"},"PeriodicalIF":2.8,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Hyperglycemia on Tear Film and Meibomian Gland Dysfunction: A Cross-Sectional Study.","authors":"Fanhua Meng, Yuan Zhou, Tong Bao, Yunlei Pang, Qinglei Shao, Lifeng Wang, Jing Zhao, Wenchao Li, Haiyan Xu, Yajun Yang, Bozhou Zhang","doi":"10.2147/DMSO.S500595","DOIUrl":"10.2147/DMSO.S500595","url":null,"abstract":"<p><strong>Purpose: </strong>Elevated blood glucose levels may disrupt tear film and meibomian gland function, contributing to dry eye disease (DED) and meibomian gland dysfunction (MGD). This study aimed to explore the relationship between hyperglycemia and DED parameters.</p><p><strong>Methods: </strong>A cross-sectional study at Chifeng Chaoju Eye Hospital (June-August 2024) included 56 participants with DED symptoms. Tear meniscus height (TMH), non-invasive tear film breakup time (FNIBUT, ANIBUT), bulbar redness, and meibomian gland atrophy (U-LAMG, L-LAMG) were assessed using a non-invasive ocular surface analyzer. Fasting blood glucose levels stratified patients into high (≥7 mmol/l) and normal (<7 mmol/l) groups, and their association with DED parameters was analyzed.</p><p><strong>Results: </strong>Among 56 patients (mean age 52.5 ± 18.0 years), those with elevated glucose levels (n=28) had more severe DED symptoms (OSDI, p = 0.046), lower TMH, FNIBUT, ANIBUT, and higher bulbar redness scores (all p < 0.05). In contrast, lower glucose levels were associated with greater U-LAMG and L-LAMG atrophy (p < 0.05). Glucose positively correlated with intraocular pressure (IOP), redness, U-LAMG, and L-LAMG but negatively correlated with TMH, FNIBUT, and ANIBUT (all p < 0.05).</p><p><strong>Conclusion: </strong>Hyperglycemia is linked to impaired tear film stability, meibomian gland function, and DED symptoms. Ocular surface disorders in individuals with diabetes may be prevented by effective glycemic control.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"327-333"},"PeriodicalIF":2.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on the Correlation of Skin Advanced Glycation End Products With Diabetic Cardiovascular Autonomic Neuropathy.","authors":"Yucheng Fang, Wu Dai, Yonghong Cao","doi":"10.2147/DMSO.S491158","DOIUrl":"10.2147/DMSO.S491158","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the correlation of advanced glycation end products (AGEs) with diabetic cardiovascular autonomic neuropathy (DCAN). Factors affecting DCAN and those related to skin AGE accumulation in patients with DCAN were analyzed.</p><p><strong>Materials and methods: </strong>A total of 192 patients with type 2 diabetes mellitus (T2DM) who were hospitalized in the Department of Endocrinology of Hefei Second People's Hospital from November 2020 to December 2022 were included and divided into DCAN (n=121) and No_DCAN (n=71) groups based on the results of Ewing test. All patients completed the detection of skin AGEs accumulation. The clinical features of the two groups were analyzed; the factors affecting DCAN were analyzed by multiple logistic regression analysis, and those related to skin AGE accumulation in patients with DCAN were analyzed by Spearman correlation analysis and Pearson correlation analysis.</p><p><strong>Results: </strong>Compared with the No_DCAN group, the combined DR ratio, fasting plasma glucose (FPG), and skin AGEs were increased in the DCAN group (all <i>P</i><0.05). Multivariate logistic regression analysis showed that FPG, combined DR, and skin AGEs all affected DCAN (<i>P</i><0.05). Spearman correlation analysis showed that skin AGE accumulation in patients with DCAN was correlated with sex (male or female) and the presence of vascular plaques (All <i>P</i><0.05). Pearson correlation analysis showed that skin AGE accumulation in patients with DCAN was correlated with age, diabetes course, diastolic blood pressure, uric acid, creatinine and UACR levels (All <i>P</i><0.05).</p><p><strong>Conclusion: </strong>Skin AGEs, combined DR and FPG affected DCAN, and skin AGEs, combined DR and FPG were closely related to the incidence of DCAN. Sex (male or female), presence of vascular plaques, age, diabetes course, diastolic blood pressure, uric acid levels, creatinine levels and UCAR levels were correlated with skin AGE accumulation in patients with DCAN.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"335-343"},"PeriodicalIF":2.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11804226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Serum HMGB1 and RAGE Levels and Restenosis in Type 2 Diabetes Mellitus Patients Complicated With Lower Extremity Vascular Disease: A Retrospective Study.","authors":"Ting Jia, Xuyan Zhang, Li Li, Xiaowan Jiang, Mengjie Wang","doi":"10.2147/DMSO.S496360","DOIUrl":"10.2147/DMSO.S496360","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the potential association between the serum concentrations of high mobility group protein B1 (HMGB1) and the receptor for advanced glycation end-products (RAGE) in relation to the occurrence of restenosis following interventional therapy for lower extremity vascular disease in patients diagnosed with type 2 diabetes mellitus (T2DM).</p><p><strong>Patients and methods: </strong>From March 2023 to January 2024, 96 T2DM patients with lower extremity vascular disease who underwent interventional therapy and 6-month follow-up in our hospital were studied. Patients were divided into in-stent restenosis (ISR) (n=38) and none-in-stent restenosis (NISR) (n=58) groups based on the occurrence of ISR. Pre-surgery demographics and serum levels of HMGB1, RAGE, glycated hemoglobin (HbA1c), and high-sensitivity C-reactive protein (hs-CRP) were analyzed. A Pearson correlation and multivariate Logistic regression were used to identify factors influencing restenosis. A predictive nomogram was built based on the identified factors. The receiver operating characteristic (ROC) curve analysis evaluated the predictive value of serum RAGE and HMGB1 for restenosis post-intervention.</p><p><strong>Results: </strong>The ISR group exhibited statistically significant elevations in HbA1c, hs-CRP, HMGB1, and RAGE levels compared to the NISR group (<i>P</i><0.05). Multivariate logistic regression analysis revealed that HMGB1 and RAGE were independent risk factors for restenosis in T2DM patients with lower extremity vascular disease undergoing interventional therapy. The predictive nomogram model developed specifically for this patient population demonstrated high accuracy. ROC curve analysis further emphasized the superior combined predictive value of HMGB1 and RAGE over individual biomarkers for restenosis after interventional therapy in this cohort.</p><p><strong>Conclusion: </strong>Elevated preoperative serum levels of HMGB1 and RAGE in T2DM patients with lower extremity vascular disease are linked to restenosis following interventional therapy.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"315-325"},"PeriodicalIF":2.8,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11803418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Approach for Biomarker Discovery and Mechanistic Insights into the Co-Pathogenesis of Type 2 Diabetes Mellitus and Non-Hodgkin Lymphoma.","authors":"Yidong Zhu, Jun Liu, Bo Wang","doi":"10.2147/DMSO.S503449","DOIUrl":"10.2147/DMSO.S503449","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) is associated with an increased risk of non-Hodgkin lymphoma (NHL), but the underlying mechanisms remain unclear. This study aimed to identify potential biomarkers and elucidate the molecular mechanisms underlying the co-pathogenesis of T2DM and NHL.</p><p><strong>Methods: </strong>Microarray datasets of T2DM and NHL were downloaded from the Gene Expression Omnibus database. Subsequently, a protein-protein interaction network was constructed based on the common differentially expressed genes (DEGs) between T2DM and NHL to explore regulatory interactions. Functional analyses were performed to explore underlying mechanisms. Topological analysis and machine learning algorithms were applied to refine hub gene selection. Finally, quantitative real-time polymerase chain reaction was performed to validate hub genes in clinical samples.</p><p><strong>Results: </strong>Intersection analysis of DEGs from the T2DM and NHL datasets identified 81 shared genes. Functional analyses suggested that immune-related pathways played a significant role in the co-pathogenesis of T2DM and NHL. Topological analysis and machine learning identified three hub genes: <i>GZMM, HSPG2</i>, and <i>SERPING1</i>. Correlation analysis revealed significant correlations between these hub genes and immune cells, underscoring the importance of immune dysregulation in shared pathogenesis. The expression of these genes was successfully validated in clinical samples.</p><p><strong>Conclusion: </strong>This study suggested the pivotal role of immune dysregulation in the co-pathogenesis of T2DM and NHL and identified and validated three hub genes as key contributors. These findings provide insight into the complex interplay between T2DM and NHL.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"267-282"},"PeriodicalIF":2.8,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activated Growth Factor From Platelets as Treatment for Diabetic Retinopathy Through Antioxidant-Oxidative Stress Pathway.","authors":"Ramzi Amin, Rachmat Hidayat, Ziske Maritska, Trisa Wulanda Putri","doi":"10.2147/DMSO.S490055","DOIUrl":"10.2147/DMSO.S490055","url":null,"abstract":"<p><strong>Background: </strong>Reactive oxygen species (ROS) is known to play a significant role in the activation of chronic inflammatory processes in diabetic retinopathy. This study was aimed to evaluate activated growth factor (AGF) from platelet for diabetic retinopathy treatment, utilizing an in vivo investigation to regulate the antioxidant-oxidative stress pathway.</p><p><strong>Methods: </strong>The activated growth factor was initially derived by extracting intravenous blood from the rats. Advanced glycation end products (AGEs), p38 mitogen activated protein kinase (p38 MAPK), nuclear factor-κβ (NF-κβ), reactive oxygen species (ROS), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), superoxide dismutase (SOD) and vascular endothelial growth factor (VEGF) was assessed using enzyme linked immunoassay (ELISA). In vivo, diabetic retinopathy rat models were induced by streptozotocin injection and were evaluated by retinal funduscopy.</p><p><strong>Results: </strong>The mean diameter of the retinal artery was significantly reduced when activated growth factor with transforming growth factor-β concentration of 10 ng/mL or 100 ng/mL was administered (p<0.05). The retinal tissue of diabetic rats showed a decline in antioxidant activity due to oxidative stress. AGF containing TGF-β (10 ng/mL and 100 ng/mL) significantly increased SOD activity (p<0.05). AGF administration effectively decreased proinflammatory cytokines like TNF-α and IL-1β.</p><p><strong>Conclusion: </strong>The study shows that AGF, with TGF-β concentrations of 10 ng/mL and 100 ng/mL, can reduce AGEs, p38MAPK, Nf-κβ, ROS, TNF-α, IL-1β, VCAM-1, ICAM-1, and VEGF in diabetic retinopathy rats' retinal tissue, while increasing antioxidant SOD concentration, suggesting AGF may help treat diabetic retinopathy by reducing inflammation and oxidative stress.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"305-313"},"PeriodicalIF":2.8,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appendicitis After Initiation of Tirzepatide.","authors":"Garrett Chan, Mariam Ansar, Marlena Klein","doi":"10.2147/DMSO.S496739","DOIUrl":"10.2147/DMSO.S496739","url":null,"abstract":"<p><p>Tirzepatide is a GLP1/GIP receptor agonist that is used to treat type 2 diabetes and promote weight loss. Common side effects of Tirzepatide include nausea, vomiting, and diarrhea. More severe side effects include pancreatitis, cholelithiasis, thyroid cancer, and cholecystitis. With the increased use of these medications, additional side effects are being discovered. Delayed gastric emptying associated with GLP1/GIP receptor agonists can increase the risk of developing appendicitis due to changes in gastrointestinal motility. There is minimal data on the risk of developing appendicitis with Tirzepatide. This novel case report presents a 73-year-old female patient, without typical risk factors or obvious triggers, who developed appendicitis one week following the initiation of Tirzepatide. Once Tirzepatide was stopped, the patient's symptoms dramatically improved and there was improvement also demonstrated on CT imaging. The patient eventually got an outpatient appendectomy. Appendicitis is not frequently reported as a GLP1/GIP receptor agonist side effect in clinical studies. There seems to be a temporal association between Tirzepatide and the onset of appendicitis. This case report highlights the importance of considering appendicitis as a potential adverse effect of Tirzepatide, a GLP1/GIP receptor agonist.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"261-265"},"PeriodicalIF":2.8,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>FTO</i> rs17817449 Variant Increases the Risk of Severe Obesity in a Brazilian Cohort: A Case-Control Study.","authors":"Kaio Cezar Rodrigues Salum, Izadora Sthephanie da Silva Assis, Úrsula de Almeida Kopke, Lohanna Palhinha, Gabriella de Medeiros Abreu, Laura Wendling Gouvêa, Myrela Ribeiro Teixeira, Fernanda Cristina C Mattos, José Firmino Nogueira Neto, Rafaela de Freitas Martins Felício, Eliane Lopes Rosado, Verônica Marques Zembrzuski, Mario Campos Junior, Clarissa Menezes Maya-Monteiro, Pedro Hernán Cabello, João Regis Ivar Carneiro, Patrícia Torres Bozza, Fabiana Barzotto Kohlrausch, Ana Carolina Proença da Fonseca","doi":"10.2147/DMSO.S451401","DOIUrl":"10.2147/DMSO.S451401","url":null,"abstract":"<p><strong>Purpose: </strong>Obesity is a complex disease caused by a combination of genetic, environmental, and epigenetic factors, and is associated with an increased risk of chronic diseases. The leptin-melanocortin pathway integrates peripheral signals about the body's energy stores with a central neuronal circuit in the hypothalamus. This pathway has been extensively studied over the years, as genetic variations in genes related to it may play a crucial role in determining an individual's susceptibility to obesity. Therefore, we analyzed the association between obesity and specific polymorphisms in leptin-melanocortin-related genes such as <i>LEPR</i> rs1137101, <i>POMC</i> rs1042571, <i>LEP</i> rs7799039, <i>BDNF</i> rs6265, <i>FTO</i> rs17817449, <i>CART</i> rs121909065, and <i>NPY</i> rs16147/rs5574.</p><p><strong>Patients and methods: </strong>The study enrolled 501 participants from Rio de Janeiro, Brazil, with obesity class II or greater (BMI ≥ 35 kg/m2) and normal weight controls (18.5≤ BMI ≤24.9 kg/m2). We collected demographic, body composition, biochemical, and genotyping data by real-time PCR, and performed logistic and linear regression analyses to investigate the association of polymorphisms with severe obesity status and obesity-related quantitative parameters.</p><p><strong>Results: </strong>Individuals with severe obesity had significantly higher anthropometric measures, blood pressure, and biochemical levels. The <i>FTO</i> rs17817449 TT genotype was associated with a significantly higher risk of developing severe obesity, and distinct cytokine expression was observed across the <i>FTO</i> rs17817449 genotypes. The <i>BDNF</i> rs6265 dominant-model and <i>NPY</i> rs16147 CC genotypes were associated with triglyceride levels and childhood obesity, respectively. Finally, individuals with obesity were more likely to carry a greater number of risk alleles than those without obesity.</p><p><strong>Conclusion: </strong>Our study observed an important association between <i>FTO</i> rs17817449 polymorphism with obesity and obesity-related traits. Additionally, <i>BDNF</i> rs6265 dominant-model was associated with triglyceride serum levels, and <i>NPY</i> rs16147 may have a role in obesity onset.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"283-303"},"PeriodicalIF":2.8,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of microRNA-139-5p Improves Fibroblasts Viability and Enhances Wound Repair in Diabetic Rats Through AP-1 (c-Fos/c-Jun).","authors":"Jiake Mo, Jiaqi Zhang, Xubiao Meng, Fang Wang, Weian Tang, Ying Liu, Lanfang Fu, Fang Liang, Zhaohui Mo","doi":"10.2147/DMSO.S496556","DOIUrl":"10.2147/DMSO.S496556","url":null,"abstract":"<p><strong>Introductions: </strong>Diabetic foot ulcers (DFU) are notoriously difficult to heal, however, its underlying molecular mechanisms are unknown. MicroRNA-139-5p participates in various biological processes, including cancer and vascular endothelial injury, while its role in diabetic wound healing has not been reported.</p><p><strong>Methods: </strong>Sprague-Dawley (SD) rats were intraperitoneally injected with streptozotocin and a 1.0 cm full-layer dorsal skin wound was made to establish a diabetic wound model. On days 1, 4, 7, and 10 after the wound was made, a solution containing microRNA-139-5p antagomir or control was injected along the dorsal edge of the wound. Wound healing was analyzed using Image J, histological analysis and molecular analysis. Skin tissues from 4 diabetic and 4 matched non-diabetic ulcer patients were obtained to detect microRNA-139-5p expression. In vitro, human skin fibroblasts were transfected with microRNA-139-5p inhibitors/mimics, the function of the fibroblasts was evaluated by CCK-8 assay and scratch assay, and AP-1 (c-Fos/c-Jun) was detected.</p><p><strong>Results: </strong>Obviously elevated microRNA-139-5p expression was detected in the wound tissue of the rats with diabetes and patients with DFUs, and the microRNA-139-5p antagonist-treated diabetic wounds had faster healing rates. The pace of diabetic wound re-epithelialization and angiogenesis was accelerated, and the expression of AP-1 family members (c-Fos/c-Jun), and VEGF, PDGF was upregulated in the wound tissue of diabetic rats treated with topical microRNA-139-5p antagomir. In vitro, the expression of microRNA-139-5p was up-regulated in human skin fibroblasts induced by high glucose treatment, while the function of the cell proliferation and migration was promoted and the level of AP-1 (c-Fos/c-Jun) was increased after transfected with the microRNA-139-5p inhibitor, and vice versa. Our study further verified that microRNA-139-5p regulated the migration of human skin fibroblasts by modulating c-Fos.</p><p><strong>Conclusion: </strong>Inhibiting microRNA-139-5p improves fibroblasts viability and promotes diabetic wound healing, suggesting that this may be a therapeutic strategy for diabetic foot ulcer.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"237-248"},"PeriodicalIF":2.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes Following Metabolic Bariatric Surgery at a Single Center in the United Arab Emirates.","authors":"Matthew Allum, Adam Buckley, Sara G I Suliman, Mohamed Suliman, Khaled Hamdan, Mohamed Al Hadad","doi":"10.2147/DMSO.S499361","DOIUrl":"10.2147/DMSO.S499361","url":null,"abstract":"<p><strong>Introduction: </strong>While the benefits of metabolic bariatric surgery (MBS) are well described, only few studies have been published from the Gulf region, where the impact of regional patient characteristics on outcomes remains poorly understood.</p><p><strong>Methods: </strong>Data were reviewed for patients attending metabolic follow-up three or more months after primary MBS at our center in the UAE from 2016 to 2022. Total weight loss (TWL), status of type 2 diabetes (T2D), hyperlipidemia, and hypertension were assessed following sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB).</p><p><strong>Results: </strong>Of 2851 included patients, 62.6% were female and 94.0% Emirati. Pre-operatively, mean age was 34.2 ±0.2 years, median BMI was 41.0 (IQR 37.8-45.2) kg/m²; 92.5% had SG and 7.5% RYGB. %TWL (95% confidence interval) for RYGB was 31.2% (30.0-32.5), 30.9% (29.0-32.9) and 28.4% (23.0-33.8) at 1, 3 and 5 years. Following SG, %TWL was 29.9% (29.5-30.3), 25.8% (25.0-26.7) and 23.4% (21.6-25.2) for the same intervals. The proportion of total operated patients included was 60.2%, 43.7% and 33.8% respectively. Men lost more weight than women 12 months after SG, with mean %TWL of 32.5% (31.8-33.2) vs 28.4% (27.9-28.9) respectively. T2D remission (HbA1c <6.5% without diabetes medications) after SG was 61.9% (179/289) at 1 year and 40.9% (18/44) at 5 years. RYGB favored T2D remission over SG at 12 months, OR=2.272 (1.152-4.65). There was no difference between procedures for hypertension status, although remission from hyperlipidemia was higher 1 year after RYGB at 41.8% (23/55) compared to SG 16.4% (78/475) (p<0.001).</p><p><strong>Conclusion: </strong>In this young Emirati cohort, RYGB was associated with more weight loss and favored T2D and hyperlipidemia remission over SG. Women lost less weight than men after SG. Weight recurrence from 1 to 5 years after SG was greater than the international average. Further research is required to explain these differences and improve outcomes.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"249-260"},"PeriodicalIF":2.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}